Vision Executives Blog

Orasis Pharmaceuticals Secures $78M to Support US Launch of Qlosi for Presbyopia

Written by Vision Executives | Oct 25, 2024 7:47:07 AM

๐Ž๐ซ๐š๐ฌ๐ข๐ฌ ๐๐ก๐š๐ซ๐ฆ๐š๐œ๐ž๐ฎ๐ญ๐ข๐œ๐š๐ฅ๐ฌ ๐’๐ž๐œ๐ฎ๐ซ๐ž๐ฌ $78 ๐Œ๐ข๐ฅ๐ฅ๐ข๐จ๐ง ๐ญ๐จ ๐’๐ฎ๐ฉ๐ฉ๐จ๐ซ๐ญ ๐”.๐’. ๐‹๐š๐ฎ๐ง๐œ๐ก ๐จ๐Ÿ ๐๐ฅ๐จ๐ฌ๐ข ๐Ÿ๐จ๐ซ #๐๐ซ๐ž๐ฌ๐›๐ฒ๐จ๐ฉ๐ข๐š

๐Ÿ’ฐ Nearly a year after receiving FDA approval, Orasis Pharmaceuticals has successfully raised $78 million in financing to back the U.S. commercial launch of its ground breaking product, Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%. This preservative-free eye drop, originally developed under the name CSF-1, is specifically designed to treat presbyopiaโ€”a common age-related condition that affects near vision.

๐ŸŒŽ The new funding will be instrumental in bringing Qlosi to the market, supporting its launch and expanding its reach across the country. This development comes at a time when the pharmaceutical industry is focusing on innovative solutions to meet the growing needs of patients with presbyopia. With Qlosiโ€™s approval, Orasis is positioning itself as a key player in this expanding market.